Syndax is a commercial-stage oncology biopharmaceutical company with two FDA-approved drugs targeting rare blood cancers. Revuforj (revumenib) is an oral, first-in-class menin inhibitor approved for relapsed/refractory acute leukemia with a KMT2A translocation and relapsed/refractory AML with an NPM1 mutation, in both adults and pediatric patients. Syndax holds worldwide rights to Revuforj and commercializes it through its own U.S. sales force. Niktimvo (axatilimab) is a first-in-class anti-CSF-1R antibody approved for chronic graft-versus-host disease (cGVHD) after two or more prior lines of therapy, and is co-commercialized in the U.S. with Incyte, which leads global commercial efforts. Syndax earns 50% of U.S. Niktimvo net profits and tiered royalties on ex-U.S. sales. Both drugs target patient populations with limited treatment options. Revuforj revenue is driven by new patient starts and treatment duration, with a compounding revenue dynamic as patients go to transplant and restart therapy as maintenance. Niktimvo's contribution grows as cGVHD patients remain on therapy for years. Syndax does not manufacture its own drugs and licenses its compounds from third parties. The company's primary growth strategy is expanding both drugs into frontline treatment settings, which Syndax estimates represents a combined U.S. opportunity exceeding $10B, with multiple Phase 3 trials underway. Axatilimab is also being evaluated in idiopathic pulmonary fibrosis, where its macrophage-targeting mechanism may address fibrosis differently from existing therapies.